| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, General Counsel and Sec
1 company
Colin Sandercock is SVP, General Counsel and Sec at CUE. Colin Sandercock's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $357K at current prices.
The CUE filings lean toward selling, a net 2,962 shares.
Colin Sandercock has 15 Form 4 filings on record from December 2017 to April 2026, all as SVP, General Counsel at Cue Biopharma (CUE), 2017–2026.
The 23 reported transactions were 15 option or other derivative awards, 3 option exercises, 3 open-market sales and 2 open-market purchases.
Counted by filing, the open-market trades come to 1 purchase worth about $133K and 2 sales worth about $398K.
The only open-market purchase was 16,938 shares of CUE at an average $7.83 on June 10, 2019, about $133K.
The largest open-market sale was 13,274 shares of CUE at an average $20.00 on August 5, 2020, about $265K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 5, 2020 | CUE Cue Biopharma, Inc. | SVP, General Counsel and Sec | Sale+OE | 13,274 | $20.00 | $265,480.00 | -43.7% | |
| Aug 4, 2020 | CUE Cue Biopharma, Inc. | SVP, General Counsel and Sec | Sale+OE | 6,626 | $20.00 | $132,530.05 | -27.9% | |
| Jun 10, 2019 | CUE Cue Biopharma, Inc. | SVP, General Counsel and Sec | Buy | 16,938 | $7.83 | $132,658.34 | New |